IGC Pharma Expands CALMA Trial Recruitment for Alzheimer's Agitation

IGC Pharma, Inc. has officially named its ongoing Phase 2 trial for agitation in Alzheimer's disease as CALMA, reflecting its goal to mitigate agitation affecting a significant portion of Alzheimer's patients globally. To boost participation, IGC Pharma has harnessed geofencing technology and social media, which initially tripled enrollment at selected sites at low costs. The strategy will now be rolled out to other trial locations in the USA and Canada. This approach aims to enhance patient and caregiver engagement in the study.

The CALMA trial seeks to evaluate the safety and efficacy of IGC-AD1, targeting 164 participants. IGC-AD1 is a potential treatment with anti-neuroinflammatory properties aimed at Alzheimer's-related agitation. This trial marks a step toward developing transformative therapies and value creation for patients and shareholders.